InsiderTrades.com logo
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.

AIM Insider Trading

Insider Ownership Percentage: 0.02%
Insider Buying (Last 12 Months): $163,253.94
Insider Selling (Last 12 Months): $0.00

AIM ImmunoTech Insider Trading History Chart

This chart shows the insider buying and selling history at AIM ImmunoTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AIM ImmunoTech Share Price & Price History

Current Price: $0.21
Price Change: +0.30 (1.20%)
As of 11/22/2024 01:00 AM ET

This chart shows the closing price history over time for AIM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Bill Gates’ is about to mint millionaires (again) with Stargate.
From Brownstone Research   |   Ad
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Click here and I’ll tell you everything you need to know.

AIM ImmunoTech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2024Stewart AppelrouthDirectorBuy81,953$0.19$15,571.07321,752View SEC Filing Icon  
11/20/2024Thomas K EquelsCEOBuy60,110$0.18$10,819.801,552,968View SEC Filing Icon  
9/16/2024Thomas K EquelsCEOBuy5,000$0.30$1,500.001,493,042View SEC Filing Icon  
5/6/2024Peter W Rodino IIICOOBuy30,865$0.41$12,654.65212,583View SEC Filing Icon  
5/6/2024Thomas K EquelsCEOBuy61,729$0.41$25,308.89778,184View SEC Filing Icon  
3/21/2024Nancy BryanDirectorBuy38,462$0.39$15,000.1838,462View SEC Filing Icon  
3/15/2024Peter W Rodino IIICOOBuy37,879$0.33$12,500.07181,718View SEC Filing Icon  
3/15/2024Stewart AppelrouthDirectorBuy90,910$0.33$30,000.30239,765View SEC Filing Icon  
3/15/2024Thomas K EquelsCEOBuy75,758$0.33$25,000.14716,455View SEC Filing Icon  
11/27/2023Thomas K EquelsCEOBuy33,861$0.44$14,898.84640,697View SEC Filing Icon  
9/29/2023Thomas K EquelsCEOBuy22,676$0.44$9,977.44606,836View SEC Filing Icon  
8/24/2023Thomas K EquelsCEOBuy14,993$0.67$10,045.31575,938View SEC Filing Icon  
7/17/2023Thomas K EquelsCEOBuy16,950$0.59$10,000.50560,945View SEC Filing Icon  
1/3/2023Stewart AppelrouthDirectorBuy80,646$0.31$25,000.26217,063View SEC Filing Icon  
1/3/2023Thomas K EquelsCEOBuy161,291$0.31$50,000.21543,995View SEC Filing Icon  
See Full Table
We recommended Nvidia in 2016, now we’re recommending this…
From Porter & Company   |   Ad
The AI boom is just getting started. And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.

SEC Filings (Institutional Ownership Changes) for AIM ImmunoTech (NYSE:AIM)

12.02% of AIM ImmunoTech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AIM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

AIM ImmunoTech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2024Armistice Capital LLC4,078,000$1.52M0.0%N/A7.919%Search for SEC Filing on Google Icon
11/16/2021Verition Fund Management LLC148,479$0.30M0.0%+37.5%0.310%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC41,095$82K0.0%-38.8%0.086%Search for SEC Filing on Google Icon
10/28/2021WINTON GROUP Ltd82,564$0.17M0.0%+50.4%0.173%Search for SEC Filing on Google Icon
10/19/2021Arkadios Wealth Advisors21,597$43K0.0%N/A0.045%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC246,000$0.53M0.0%-9.2%0.514%Search for SEC Filing on Google Icon
8/16/2021Schonfeld Strategic Advisors LLC23,100$49K0.0%-40.0%0.048%Search for SEC Filing on Google Icon
8/16/2021State Street Corp160,413$0.35M0.0%N/A0.335%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC152,848$0.33M0.0%-68.1%0.320%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp87,226$0.19M0.0%+28.8%0.182%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.1,993,156$4.29M0.0%+3.5%4.167%Search for SEC Filing on Google Icon
8/12/2021XTX Topco Ltd29,269$63K0.0%N/A0.061%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP139,160$0.30M0.0%N/A0.291%Search for SEC Filing on Google Icon
8/10/2021WINTON GROUP Ltd54,894$0.12M0.0%N/A0.115%Search for SEC Filing on Google Icon
6/4/2021Lehman & Derafelo Financial Resources LLC11,100$25K0.0%N/A0.023%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC29,484$67K0.0%-71.6%0.062%Search for SEC Filing on Google Icon
5/18/2021Verition Fund Management LLC108,000$0.25M0.0%+80.0%0.226%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley2,505,954$5.69M0.0%+150.9%5.240%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC103,283$0.23M0.0%N/A0.216%Search for SEC Filing on Google Icon
5/17/2021Schonfeld Strategic Advisors LLC38,500$88K0.0%N/A0.081%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC478,759$1.09M0.0%N/A1.001%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC351,750$0.80M0.0%+49.7%0.736%Search for SEC Filing on Google Icon
5/11/2021Rockefeller Capital Management L.P.40,000$90K0.0%+100.0%0.084%Search for SEC Filing on Google Icon
5/10/2021HighTower Advisors LLC63,095$0.14M0.0%N/A0.132%Search for SEC Filing on Google Icon
5/10/2021GSA Capital Partners LLP74,790$0.17M0.0%+338.7%0.156%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.979,042$2.22M0.0%+91.7%2.047%Search for SEC Filing on Google Icon
5/7/2021Cambridge Investment Research Advisors Inc.46,679$0.11M0.0%+14.7%0.098%Search for SEC Filing on Google Icon
5/4/2021Community Bank N.A.13,226$30K0.0%N/A0.028%Search for SEC Filing on Google Icon
4/21/2021Lehman & Derafelo Financial Resources LLC11,100$25K0.0%N/A0.023%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC103,807$0.19M0.0%+250.7%0.255%Search for SEC Filing on Google Icon
2/18/2021Verition Fund Management LLC60,000$0.11M0.0%+50.0%0.147%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.510,796$0.91M0.0%+1.6%1.255%Search for SEC Filing on Google Icon
2/4/2021Cambridge Investment Research Advisors Inc.40,679$73K0.0%+19.0%0.100%Search for SEC Filing on Google Icon
2/4/2021GSA Capital Partners LLP17,047$31K0.0%-82.2%0.042%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC29,604$64K0.0%-55.5%0.073%Search for SEC Filing on Google Icon
11/13/2020Morgan Stanley805,415$1.73M0.0%+69.1%2.029%Search for SEC Filing on Google Icon
11/12/2020JPMorgan Chase & Co.17,369$37K0.0%+868,350.0%0.044%Search for SEC Filing on Google Icon
11/9/2020LPL Financial LLC20,500$44K0.0%N/A0.052%Search for SEC Filing on Google Icon
11/6/2020BlackRock Inc.502,692$1.08M0.0%+5.7%1.267%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
AIM ImmunoTech logo
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Read More on AIM ImmunoTech

Today's Range

Now: $0.21
Low: $0.21
High: $0.22

50 Day Range

MA: $0.26
Low: $0.19
High: $0.32

52 Week Range

Now: $0.21
Low: $0.16
High: $0.62

Volume

367,417 shs

Average Volume

684,507 shs

Market Capitalization

$13.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of AIM ImmunoTech?

AIM ImmunoTech's top insider investors include:
  1. Thomas K Equels (CEO)
  2. Stewart Appelrouth (Director)
  3. Peter W Rodino III (COO)
  4. Nancy Bryan (Director)
Learn More about top insider investors at AIM ImmunoTech.
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.